Unusual option activity rolling out thru June on the 60 calls trading over 60,000 contracts. Somebody is making a huge bet . In recent months this stock has had a spectacular rise . Earnings are expected at the end of October 2019.  Buffetts Mistakes - Airlines Cyclical Disasters

Six analysts rate this stock a STRONG BUY We urge serious investors to take a long look at these shares for long term growth

Recent advances in immunotherapy outperforming chemo in a lung cancer study has driven these shares upward.
About 40% of patients who received a combination of Bristol-Myers Squibb’s immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer were alive after two years. 

 Drones Are Coming - UPS Gets FAA Approval

The combination outperformed chemotherapy as a first-line treatment for the most common form of lung cancer, with 33% of patients who got the older therapy still alive after two years, the company said.

Apple Upgrade Drives Stock Higher - Target $265

Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

 Investors will be hoping for strength from BMY as it approaches its next earnings release, which is expected to be October 31, 2019. The company is expected to report EPS of $1.06, down 2.75% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.83 billion, up 2.36% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.29 per share and revenue of $24.07 billion. These totals would mark changes of +7.79% and +6.69%, respectively, from last year.

Advanced Micro - Powerful New Chips - Strong Buy Rating  

Investors should also note any recent changes to analyst estimates for BMY. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.25% higher within the past month. BMY is holding a Zacks Rank of #3 (Hold) right now.

Investors should also note BMY's current valuation metrics, including its Forward P/E ratio of 11.71. This represents a discount compared to its industry's average Forward P/E of 14.47.

We can also see that BMY currently has a PEG ratio of 2.47. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.12 based on yesterday's closing prices.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 40% of all 250+ industries.